Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement that the Group has obtained drug production registration approval from China's National Drug Administration for norepinephrine bitartrate injection (1ml: 2mg). It is a category 3 chemical drug. It is considered a consistent evaluation, and is mainly used for blood pressure control in certain acute hypotensive states.
The clinical need for adrenaline first aid drugs is just now strong, and the annual domestic usage is estimated to be about 200 million. The Group's norepinephrine bitartrate injection (4ml: 8mg) was approved in the early stages. This time, a new 1ml:2mg specification was added. The small size is more suitable for refined dosage scenarios such as initial administration, reduced-dose titration, and pediatric patients, improving clinical dosage flexibility. Up to now, the Group has prepared four products: adrenaline hydrochloride injection, norepinephrine bitartrate injection, isoproadrenaline hydrochloride injection, and phenoxyadrenaline hydrochloride injection. The epinephrine series product portfolio has outstanding advantages, and also has independent support for the four APIs in this series. It is one of the few domestic enterprises with integrated production capacity for this series of four kinds of pharmaceutical ingredients. The industrial chain has significant advantages of autonomy and control.
The Group's paracetaminophen mannitol injections (50ml and 100ml specifications) have obtained approval from the State Drug Administration for additional indications to be used in combination with opioid analgesics to relieve moderate to severe pain in adults after surgery.
Previously, the Group's acetaminophen mannitol injection was approved as an indication to relieve fever in adults. The Group is the first in China to be approved for both antipyretic and analgesic indications. This approval will make the Group's acetaminophen mannitol injections more widely used and the market size larger.